AWE
发表于 2025-3-23 12:32:45
http://reply.papertrans.cn/19/1819/181820/181820_11.png
惊呼
发表于 2025-3-23 15:14:18
https://doi.org/10.1007/978-3-319-11839-0ch to evaluating treatment effects of targeted therapies and immunotherapies. Under the basket trial, patients with the same genetic or molecular aberrations, regardless of their cancer types, are enrolled in the trial for evaluating the effect of a targeted agent. The basket trial allows for the in
Acumen
发表于 2025-3-23 20:32:06
https://doi.org/10.1007/978-3-319-11839-0dous advances in biomedical research, a number of candidate drugs are produced and discovered at an unprecedented speed. This makes the traditional one-treatment-at-a-time phase II trial paradigm cumbersome and grossly inefficient. Platform trials, also known as multi-arm multi-stage trials, provide
安抚
发表于 2025-3-23 22:42:49
http://reply.papertrans.cn/19/1819/181820/181820_14.png
环形
发表于 2025-3-24 04:45:45
http://image.papertrans.cn/b/image/181820.jpg
modish
发表于 2025-3-24 06:40:36
http://reply.papertrans.cn/19/1819/181820/181820_16.png
600
发表于 2025-3-24 10:42:35
Introduction to Phase I Dose-Finding Clinical Trialsnvestigated in subsequent phases of development. This chapter review several novel phase I designs for oncology, including the continual reassessment method (CRM), modified toxicity probability interval design (mTPI), Keyboard design, and Bayesian optimal interval design (BOIN). Characteristics of t
Gyrate
发表于 2025-3-24 18:48:52
Phase I Designs for Late-Onset Toxicityexisting phase I designs, which require that toxicity can be observed quickly to inform the dose assignment for the next new cohort of patients. This chapter introduces three model-based designs, including the time-to-event CRM (TITE-CRM), fractional CRM (fCRM), data augmentation CRM (DA-CRM), and a
Decibel
发表于 2025-3-24 19:36:17
http://reply.papertrans.cn/19/1819/181820/181820_19.png
赏钱
发表于 2025-3-25 01:45:26
Model-Based Designs for Identification of Optimal Biological Doseal., 2014), a Bayesian phase I/II design for immunotherapy (Liu et al., 2018), and an isotonic design (Zang et al., 2014). These designs assume a dose-toxicity and dose-efficacy model, and continuously update the estimate of the model in a way similar to the continual reassessment method (CRM). The